Vascular Biosciences Shares Recent Advances in Pulmonary Hypertension Research
David Mann, CEO of Vascular Biosciences (VBS), shares a series of recent research articles outlining our continued efforts at advancing the treatment and management of pulmonary arterial hypertension.
A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy
This article describes a bioinformatics approach for ranking currently approved pulmonary arterial antihypertensive agents based on gene expression data derived from percutaneous endoarterial biopsies in an animal model of pulmonary arterial hypertension (PAH). A new potential paradigm in the therapy for PAH is introduced, which would include endoarterial biopsy, molecular analysis and tailored pharmacological therapy for patients with PAH.
This scientific paper can be read at:
Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension
This article illustrates the therapeutic potential of a combination therapy using fasudil, a Rho-kinase inhibitor, and DETA NONOate (DN), a nitric oxide donor, in CAR targeted liposomes intratracheally delivered in a Sugen/hypoxia model of severe pulmonary arterial hypertension (PAH).
This article can be read at:
CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension
This article explores whether co-administration of the homing peptide CAR (CARSKNKDC) improves the vasodilatory selectivity of fasudil in a porcine pulmonary hypertension model.
This article can be read at: